Hearts and Minds Investments (HM1) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
5 Jun, 2026Executive summary
Reported total comprehensive income after tax of $115.3 million for the half year ended 31 December 2024, up from $13.9 million in the prior corresponding period.
Achieved a pre-tax investment return, less expenses, of 23.6% for the half year, driven by realised gains, strong Core Portfolio performance, and a weaker Australian dollar.
Post-tax NTA increased by 16.2% over the half year, prior to the payment of a fully franked dividend of 7.5 cents per share in October 2024.
Share price rose 20% over the half year, with total shareholder return of 23% including dividends.
Philanthropic donations of $4.5 million paid and $5.6 million accrued to medical research organisations during the period.
Financial highlights
Net income for the period was $91.95 million, up from $14.55 million in the prior half year.
Total comprehensive income reached $115.29 million, compared to $13.95 million a year earlier.
Basic and diluted EPS was 40.15 cents, up from 6.36 cents in the prior period.
Pre-tax NTA per share increased from $3.05 to $3.47 after dividend payment, a 13.8% rise.
Since inception in November 2018, annualised investment performance stands at 12.3%.
Outlook and guidance
Next half-year fully franked dividend of 8.0 cents per share declared, payable on 17 April 2025.
Board supports increased dividend based on strong investment performance and profit growth.
Continued focus on delivering both financial and social returns through investment and philanthropy.
As of 7 February 2025, pre-tax NTA per share was $3.91 and post-tax NTA per share was $3.60.
Latest events from Hearts and Minds Investments
- FY24 saw an 11.7% portfolio return, 20% shareholder return, and increased fully franked dividends.HM1
H2 20249 Jun 2026 - FY25 saw a 25.5% portfolio return, higher dividends, and strong support for medical research.HM1
H2 20259 Jun 2026 - Flat returns and a major write-down led to a sharp profit drop, but the interim dividend was raised.HM1
H1 20265 Jun 2026 - Strong returns, higher dividends, and active management drive performance and philanthropy.HM1
AGM 20243 Feb 2026 - Strong returns, rising dividends, and major medical research funding highlighted at AGM.HM1
AGM 202526 Nov 2025